Cannabidiol para la epilepsia resistente a fármacos en Argentina: evaluación de tecnología sanitaria

Hasdeu, Santiago; Álvarez, Jorgelina; Milone, Caterina; Sanguine, Verónica; Lamfre, Laura; Venturini, Nasim Iusef.
Rev. argent. salud publica ; 14: 1-10, 20 de Enero del 2022.
Artigo em Espanhol | LILACS, ARGMSAL, BINACIS, BRISA | ID: biblio-1377840

Documentos relacionados

  1. La guía farmacoeconómica una herramienta útil en salud pública
  2. Políticas de regulación de precios de medicamentos: consideraciones desde la economía de la salud
  3. Cannabidiol Discovery and Synthesis-a Target-Oriented Analysis in Drug Production Processes.
  4. Impact of the legalisation of recreational cannabis use.
  5. Cannabidiol pharmacotherapy for delta-9-tetrahidrocannabinol dependence
  6. Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview.
  7. Benefits, toxicity and current market of cannabidiol in edibles.
  8. Availability of biological cancer drugs under research: registration and price in Brazil, Colombia, and Mexico
  9. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
  10. An approach to the evaluation of the potency of cannabis resin in Madrid: A health hazard?